NCT04337593

Combination of Basiliximab and Pegaspargase in the Treatment of ENKTCL

Combination of Basiliximab and Pegaspargase in the Treatment of Relapsed/Refractory Extranodal NK/T-cell Lymphoma, Nasal Type: a Single Arm, Open Label, Phase 2 Trial

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: Beijing Tongren Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the efficacy and safety of Basiliximab in combination with pegaspargase in the treatment of relapsed/refractory NK/T-cell lymphoma.

Detailed description

The investigators previously found that CD25 was elevated in patients who were resistant to chemotherapy, and CD25 can mediate resistance, which can be reversed by targeting CD25 therapy. Thus, the purpose of this study is to evaluate the efficacy and safety of Basiliximab in combination with pegaspargase in the treatment of relapsed/refractory NK/T-cell lymphoma.

Conditions

• Extranodal NK/T-cell Lymphoma

Interventions

Type	Name	Description
DRUG	Basiliximab	20mg d1,8, repeated every 3 weeks
DRUG	Pegaspargase	2500IU/㎡, d1,repeated every 3 weeks

Timeline

• Start date: 2020-06-01
• Primary completion: 2022-05-31
• Completion: 2022-12-31
• First posted: 2020-04-07
• Last updated: 2020-04-07